According to Deutsche Bank, Edwards Lifesciences EW transcatheter heart valve (THV) sales were $72.7M (inclusive of $2-$3M in stocking) and were ahead of DB est of $68M.
Deutsche Bank said that sales were also higher than 4Q10's $65.3M (which included $3-4M in stocking) and well ahead of the year ago's $39.1M. EW has had the pedal to the metal; the ramp-up has been nothing short of impressive. “Two years ago the market doubted EW's ability to generate annual sales of $73M, let alone expect it for a single quarter. However, we feel expectations are now more aligned and reflected in the stock. We rate EW Hold.”
Edwards Lifesciences closed yesterday at $84.36.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsDeutsche BankEdwards LifesciencesHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in